---
schema_version: "secwatch.filing_event.v1"
accession: "0001683168-24-003598"
form_type: "8-K"
ticker: "PHIO"
cik: "0001533040"
company_name: "Phio Pharmaceuticals Corp."
filed_at: "2024-05-17T23:59:59+00:00"
generated_at: "2026-06-01T15:33:12.048495+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.4
calibrated_materiality_score: 0.4
confidence: "high"
source: SEC EDGAR
---

# Phio Pharmaceuticals enters purchase agreement with Triton Funds for up to $621k at $0.72 per share

## Summary
- Up to 862,500 shares at $0.72/share, representing ~18.8% of outstanding shares.
- Gross proceeds up to $621,000; agreement expires Nov 17, 2024 or upon full sale.
- Triton has covenanted not to engage in any short selling of PHIO common stock.
- Offered under existing shelf registration; prospectus supplement to be filed.
- Company may request purchases in one or more transactions based on market conditions.

## SEC filing metadata
- accession: 0001683168-24-003598
- form_type: 8-K
- ticker: PHIO
- cik: 0001533040
- company_name: Phio Pharmaceuticals Corp.
- filed_at: 2024-05-17T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.4
- calibrated_materiality_score: 0.4
- confidence: high
- sec_items: 1.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1533040/000168316824003598/0001683168-24-003598-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1533040/000168316824003598/phio_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001683168-24-003598
- JSON: https://secwatch.observer/filing/0001683168-24-003598.json
- Plain text: https://secwatch.observer/filing/0001683168-24-003598.txt

## Key facts
- Material Agreements
  Phio Pharmaceuticals Corp. entered into Purchase Agreement with Triton Funds LP valued at $621,000 (effective 2024-05-16).
  - Action: entry
  - Agreement: equity purchase
  - Counterparty: Triton Funds LP
  - Value: $621,000
  - Effective: 2024-05-16
  source text: On May 16, 2024, Phio Pharmaceuticals Corp., a Delaware corporation (the “Company”) entered into a purchase agreement (the “Purchase Agreement”) with Triton Funds LP (“Triton”), pursuant to which the Company agreed to sell, and Triton agreed to purchase, upon the Company’s request in one or more transactions, up to 862,500 shares of the Company’s common stock, par value $0.0001 per share, providing aggregate gross proceeds to the Company of up to $621,000.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1533040/000168316824003598/0001683168-24-003598-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.